Inovio Pharmaceuticals, Inc.
Here’s whether Inovio Pharmaceuticals, Inc. (INO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: above the 50-day MA (medium-term momentum positive); RSI 56 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-8.92% over 10 days); weak 1-year return of -32.7%; 3-month momentum negative (-16.1%); rising volume on a downtrend (distribution, 1.29x avg). Currently 63.4% off its 52-week high. Score: -3/7.
INO is trading below its 200-day MA ($1.50) — a key warning sign the longer-term trend is under pressure. An RSI of 56.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -32.7% compares to +20.4% for SPY (trailed the market by 53.1%). The current 63.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.